Recombinant Human Ephrin-A4/EFNA4 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-02224P-100UG
Human Ephrin-A4 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Human Ephrin-A4/EFNA4 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-02224P-100UG
Collections: Recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Human Ephrin-A4/EFNA4 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Leu26-Gly171. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | P52798 |
Target Symbol | Ephrin-A4/EFNA4 |
Synonyms | Ephrin-A4; LERK-4; EFNA4; EPLG4; EFL4 |
Species | Human |
Expression System | HEK293 |
Tag | C-His |
Expression Range | Leu26-Gly171 |
Mol. Weight | The protein has a predicted MW of 17.5 kDa. Due to glycosylation, the protein migrates to 18-25 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | The affinity constant of 0.113 uM as determined in SPR assay (Biacore T200). Contact us for detailed testing images. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | Ephrin A4 is one of the ephrin ligand molecules belonging to the tyrosine kinases receptor family. It was originally identified in a T-lymphoma cell line and seen to be expressed in human adult tissue as well as several tumor types. The cytoplasmic pattern of ephrin A4 could identify a subgroup of primary osteosarcoma patients with a high liability for progression, poor prognosis, and inferior response to chemotherapy. |